SMARTO ONE

PreclinicalSmall molecule

MMei Han

SMARTO ONE is one of 10 small molecule programs targeting Neurodegenerative Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurodegenerative DiseaseActive, not recruiting

Neurodegenerative DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Neurodegenerative Disease

#DrugCompanyPhaseTrials

Nuplazid

AACADIA Pharmaceuticals Inc.

Approved

3 2

Robitussin

Aricept

1 4

Namenda

AbbVie

Preclinical

1 5

THK-5351

JJae Seung Kim

Phase 2

1 6

Intropin

Pfizer

Preclinical

—7

MC225

UUniversity Medical Center Groningen

Phase 2

1 8

Citicoline

UUniversity of Texas Southwestern Medical Center

SNP318

1 10

SMARTO ONE

MMei Han

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurodegenerative Disease1 trial

Single Arm Clinical Trial of Small Molecule Natural Flavonoid Compounds for Intervention in Neurodegenerative Diseases

Unknown status·MMei Han·N/A·NCT05947409·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SMARTO ONE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SMARTO ONE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SMARTO ONE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mei Han company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMei Han

SMARTO ONE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neurodegenerative Disease1 trial

References

Drug Info

Quick Facts

Related News